SPONSORSHIP
Vaccination of the Brazilian target population with QIV is expected to result in an important benefit to public health leading to influenza-related costs avoided when compared to TIV vaccination.
CONCLUSION
•
DISCUSSION
There is a significant reduction in the number of influenza infections, health outcomes and resources use in Brazil when adding a second influenza B lineage to the influenza vaccine.
According to this model, the potential benefit of using QIV instead of TIV depends on the following input data of the economic model: variability of the influenza viruses under circulation, vaccine coverage and effectiveness by age group and use of resources.
Under the Societal perspective, the budget impact reduction was superior due to workdays saved and hospitalization/GP consultation higher costs when compared to the Public Healthcare System perspective.
A greater reduction impact in terms of health outcomes and economy in the year of 2013 would be observed because of the mismatch between B strains in that year.
Finally herd effect was not taken into account underestimating the potential impact of QIV.
• The current standard of influenza vaccination is an annual trivalent influenza vaccine (TIV), which contains three influenza strains (one A/H1N1 strain, one A/ H3N2 strain and one B strain). The strains are defined based on what is expected to circulate in the upcoming influenza season. 4 However, co-circulation of two distinct influenza B lineages (Victoria and Yamagata) and difficulties in predicting which one will predominate in the next season led to the development of the quadrivalent influenza vaccine (QIV). 5 QIV, recently licensed in Brazil, may provide better protection for the population since it would eliminate a mismatch in lineage between the vaccine strain and the circulating strain. 6
A static model published by Reed et al. in 2012 6 that estimated the public health impact of QIV compared to TIV over the last 10 seasons in the United States, was adapted to Brazil for the period from 2010 to 2013.
The analysis included the population considered at risk for influenza by the National Immunization Program (NIP), which was stratified per age groups: children, adults with comorbidities and elderly aged 60 years and older.
Inputs considered were: virological circulation, vaccine effectiveness, vaccine coverage, illness incidence, morbidity, mortality and influenza-related costs.
Data on the distribution of circulating strains over the seasons was scarce and only available from 2010 to 2013 from the cases reported by the Sentinel Surveillance Program (São Paulo State). 7 Proportion of B-lineage was based on Sao Paulo data ( Attack rates by age group were obtained from international sources. [9] [10] [11] Vaccine effectiveness by strain and per age group in the Brazilian population was not available; therefore, vaccine effectiveness from Clements et al. 12 was applied, which took into account B-lineage cross-protection assumed to be around 70% of the effectiveness against the matched B lineage.
Vaccine coverage was derived from a Brazilian source. 13 Vaccine composition corresponded to the southern hemisphere formulation. 14 Rates of a general practitioner consultation, hospitalization and death were obtained from a 2007 paper by Molinari et al. 15 Numbers of workdays lost were estimated from a local source. 16 Unit costs were obtained from the Brazilian public healthcare system database (DATASUS). 16 Direct and indirect (productivity loss) influenza-related costs were estimated from the Public Healthcare System and Society perspectives.
Costs were expressed in 2015 Brazilian Real and the exchange rate used was 1.00 USD = 3.14 BRL. The costs of vaccines were not considered. A deterministic sensitivity analyses (DSA) was performed in order to assess the robustness of the model and the impact of uncertainty on results. Results of the DSA performed on total societal costs that were avoided are presented in Figure 1 .
The major variation was caused by changes in attack rate: cost ranged from USD 19,557,444 to USD 29,336,166 (Figure 1 ).
• 
RESULTS
Over the 2010-2013 period, QIV would have prevented 674,169 cases; 329,061 GP consultations; 7,946 hospitalizations and 1,151 deaths due to influenza in the population of interest ( Table 2) .
Strain mismatch was seen in seasons 2010, 2012 and 2013. In 2011, QIV would not have had any impact as Victoria was included in the TIV and it was the only B-lineage strain circulating. 
